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PTEN is a tumor suppressor gene mutated in human cancers.
Although many mutations target the phosphatase domain, others
create a truncated protein lacking the C-terminal PDZ-binding
motif or a protein that extends beyond the PDZ-binding motif.
Using the yeast two-hybrid system, we isolated a membrane-
associated guanylate kinase family protein with multiple PDZ
domains [AIP-1 (atrophin interacting protein 1), renamed MAGI-2
(membrane associated guanylate kinase inverted-2)]. MAGI-2 con-
tains eight potential protein–protein interaction domains and is
localized to tight junctions in the membrane of epithelial cells.
PTEN binds to MAGI-2 through an interaction between the PDZ-
binding motif of PTEN and the second PDZ domain of MAGI-2.
MAGI-2 enhances the ability of PTEN to suppress Akt activation.
Furthermore, certain PTEN mutants have reduced stability, which is
restored by adding the minimal PDZ-binding motif back to the
truncated protein. We propose that MAGI-2 improves the effi-
ciency of PTEN signaling through assembly of a multiprotein
complex at the cell membrane.
Somatic mutations of the PTEN tumor suppressor gene (alsoknown as MMAC1 or TEP1) occur in many human malig-
nancies (1–3). Germ-line mutations of PTEN are found in
patients with two cancer predisposition syndromes (4, 5), and
mice with heterozygous disruption of PTEN develop multiple
tumors (6–8). Expression of PTEN suppresses the growth of
glioblastoma cells (9). PTEN encodes a cytoplasmic phosphatase
with both protein and lipid phosphatase activity, and many
mutations cause loss of enzymatic function (10–12). Candidate
substrates for PTEN include focal adhesion kinase and phos-
phatidylinositol (PI) lipids phosphorylated at the 39 position by
PI3-kinase (11, 13). Recent work has implicated the PI3-kinasey
Akt pathway as a target of PTEN in cancer cells (14–19).
PTEN contains a 220-aa C-terminal region that is also a target
of mutations in tumors. Many frameshift mutations lead to
premature truncation of the protein in exons 8 or 9 (12). Because
the last 4 aa of PTEN encode a PDZ domain-binding motif, all
C-terminal mutations would be expected to disrupt this protein–
protein interaction. PDZ domains are protein–protein interac-
tion domains that bind to consensus motifs (SyTXV) in the C
terminus of partner proteins or, alternatively, to other PDZ
domains or b-hairpin finger motifs present internally in the
partner protein (20, 21). PDZ domains are found in many types
of proteins, including a family of membrane associated scaffold
proteins known as MAGUKs (membrane-associated guanylate
kinases). MAGUKs generally contain 3–5 PDZ domains, a
catalytically inactive guanylate kinase domain, and several Src
homology or WW domains, all of which function primarily as
protein–protein interaction modules. Well-characterized
MAGUK proteins such as PSD-95 (postsynaptic density) are
believed to play a critical role in signal transduction through
clustering of associated proteins at critical structures in the
membrane such as synapses, ion channels, and tight junctions
(22, 23). The multi-PDZ domain Drosophila scaffold protein
InaD, which functions in photoreceptor signal transduction,
enhances stability of its partner proteins through PDZ domain-
mediated interactions (24). It is proposed that MAGUKs func-
tion as scaffold proteins to assemble multiprotein signaling
complexes and enhance their stability, thereby increasing the
efficiency of signal transduction (25).
To test the hypothesis that PTEN binds to a PDZ domain-
containing protein, we performed a yeast two-hybrid screen to
isolate such proteins. We identified the multi-PDZ domain-
containing MAGUK protein AIP-1 [atrophin interacting pro-
tein; renamed MAGI-2 (membrane associated guanylate kinase
inverted-2)]. MAGI-2 originally was isolated based on its inter-
action with atrophin-1, a protein containing polyglutamine
repeats in patients with a neurological disorder known as
dentatorubral and pallidoluysian atrophy (26). Here we show
that PTEN binds to MAGI-2 through an interaction between the
C terminus of PTEN and the second PDZ domain of MAGI-2.
MAGI-2 enhances the efficiency of PTEN signaling and PTEN
mutants that fail to bind MAGI-2 show defects in Akt regulation.
We propose that: (i) MAGI-2 functions as a scaffold protein to
regulate PTEN activity through assembly of a multiprotein
signaling complex, and (ii) the truncated PTEN proteins found
in some tumors are loss of function mutants because of the
combined effects of protein instability and failure to bind
MAGI-2.
Materials and Methods
Plasmids. Wild-type PTEN and PTEN mutants were FLAG-
tagged at the N terminus and cloned into pcDNA3 or the
retroviral vector pSRaMSVtkNeo (16). Full-length hemagglu-
tinin (HA)-MAGI-2 was constructed by adding an HA epitope
at the N terminus of a full-length MAGI-2 cDNA (26). The
individual MAGI-2 PDZ domain constructs were cloned into
pcDNA3.
Protein Analysis. The yeast two-hybrid screen was performed by
using the C124S PTEN mutant cloned into pAS2.1 (CLON-
TECH). Independent clones (2 3 106) from a normal human
prostate cDNA library fused to the Gal4 activation domain
(CLONTECH) were screened.
In vitro transcriptionytranslation reactions were performed by
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using rabbit reticulocyte lysate (Promega) in the presence of
[35S]methionine (Amersham Pharmacia). The product was di-
luted 1:100 in buffer containing 20 mM Hepes (pH 7.4), 150 mM
NaCl, 10% glycerol, protease inhibitors, and 0.1% Triton X-100
and incubated with glutathione S-transferase (GST) fusion
proteins bound to glutathione beads for 45 min at room
temperature.
293T cells were lysed in 1% Triton buffer 24 h after transfec-
tion. Lysates were diluted 1:10 in buffer containing no detergent,
incubated with anti-FLAG M2 antibody overnight, then incu-
bated with protein A Sepharose beads for 2 h, run on an
SDSyPAGE gel and blotted with anti-HA antibody 12CA5 to
detect MAGI-2 or anti-FLAG antibody to detect PTEN.
Fresh mouse brain was isolated and homogenized in 2 mM
EDTA, 25 mM Hepes (pH 7.5), 150 mM NaCl, 0.5% NP-40, and
10% glycerol. MAGI-2 was immunoprecipitated by using rabbit
polyclonal antisera raised against the WW domains of S-SCAM
(synaptic scaffolding molecule), the rat homologue of MAGI-2
(27). PTEN was immunoprecipitated by using rabbit polyclonal
antisera (28). Immunoblots were analyzed by using rabbit poly-
clonal antisera raised against a GST-MAGI-2 fusion protein that
spans the WW domains and first two PDZ domains.
Pulse–chase experiments were performed in 293T cells by
transfection with appropriate plasmids. Cells were cultured for
24 h with 500 mCi of [35S]methionine in methionine-free media,
then chased with unlabeled complete media for 0–72 h. Cells
were lysed, and PTEN was immunoprecipitated by using anti-
FLAG antibody.
Results
Isolation of the MAGUK Protein MAGI-2 as a PTEN-Interacting Protein.
To identify candidate proteins that bind PTEN, we performed a
yeast two-hybrid screen using a PTENyGal4 fusion protein as
bait. We isolated two different cDNAs from overlapping regions
of AIP-1. Both clones interacted with PTENyGal4 but not with
a control lamin CyGal4 protein in the yeast two-hybrid assay, as
measured by growth in nutrient depleted (His2) media and by
expression of b-galactosidase (not shown). AIP-1 is a member of
the MAGUK family of proteins. It contains one guanylate kinase
domain, two WW domains, and six PDZ domains (Fig. 1A) and
is expressed at high levels in brain and at lower levels in all tissues
tested, including prostate (26). The closest human homologue of
AIP-1 is AIP-3 (also called BAP1), which also was isolated on
the basis of its interaction with atrophin-1 (26, 29). The rodent
homologues of AIP-1 and AIP-3, respectively are S-SCAM
(synaptic scaffolding molecule) (27), which binds to a proline-
rich adaptor protein, SAPAP, involved in membrane targeting of
neuronal cell proteins, and MAGI-1 (30). To clarify the nomen-
clature for this growing family of inverted repeat MAGUKs, we
propose that AIP-1 be renamed MAGI-2.
MAGI-2yPTEN Complexes. Sequence analysis of the two MAGI-2
clones that bound PTEN showed that the smallest clone isolated
Fig. 1. PTEN binds MAGI-2 through a PDZ domain-mediated interaction. (A) Structure of MAGI-2. The two clones isolated in the two-hybrid screen (clones 4.1
and 20.1) are indicated by arrows. PDZ0 indicates a probable PDZ domain that does not have the consensus GLGF sequence. The numbering of PDZ domains 1–5
is based on the previously published nomenclature for MAGI-1 (30). GuK, guanylate kinase domain. (B) 35S-labeled in vitro transcribedytranslated MAGI-2 protein
from clone 20.1 and clones of individual PDZ domains 2 or 4 was pulled down with GST alone or full-length PTEN-GST beads. Input represents 20% of the protein
used. The bottom panel shows Coomassie staining of protein bound to beads. (C) 293T cells were transfected with wild-type (wt) or mutant FLAG-PTEN constructs
and HA-MAGI-2. Lysates were immunoprecipitated (IP) with anti-FLAG antibody and immunoblotted with anti-HA antibody 12CA5 to detect MAGI-2 or
anti-FLAG antibody to detect PTEN. (D) Transfection and immunoprecipitation (IP) were performed in 293T cells as indicated in C. (E) MAGI-2 was immunopre-
cipitated (IP) from the homogenate of fresh mouse brain (lane 4) by using antisera raised against the WW domains of S-SCAM (synaptic scaffolding molecule),
the rat homologue of MAGI-2 (27). PTEN was immunoprecipitated (lane 5) by using polyclonal antisera (28) or an independently derived PTEN antibody (19) (not
shown). Anti-Akt polyclonal antisera (New England Biolabs) (lane 3), pre-IP lysate (lane 6), and no lysate (lane 7) were used as controls. Immunoblots were
analyzed by using rabbit polyclonal antisera against GST-MAGI-2.
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(20.1) encodes PDZ domains 2–4, suggesting that one or more
of these three PDZ domains is responsible for binding to PTEN.
We tested this hypothesis by asking whether a GST-PTEN fusion
protein could bind to individual PDZ domains isolated from
MAGI-2. As expected, protein translated in vitro from clone 20.1
bound to GST-PTEN beads but not with GST alone (Fig. 1B),
confirming the results from the two-hybrid experiment. Further-
more, GST-PTEN bound to PDZ domain 2 specifically.
To determine whether binding between MAGI-2 and PTEN
also occurs in cells, we performed coimmunoprecipitation ex-
periments. A full-length HA-MAGI-2 clone was transfected into
293T cells together with wild-type PTEN or PTEN C124S
constructs, both of which contain a FLAG epitope. HA-MAGI-2
protein was detected in anti-FLAG immunoprecipitates of wild-
type PTEN and PTEN C124S, but not in cells that were not
transfected with PTEN (Fig. 1C). We asked whether PTEN
C-terminal truncation mutants that lack the PDZ binding motif
bind to MAGI-2. We created two truncation mutants, PTEN
1–337 and PTEN 1–377, which lack 66 or 26 aa from the C
terminus of PTEN based on mutations identified in human
tumors (1, 31). HA-MAGI-2 coprecipitated with wild-type
PTEN but not with PTEN 1–337 or PTEN 1–377 (Fig. 1D).
These results provide evidence that the MAGI-2yPTEN com-
plex is formed by direct interaction between PDZ domain 2 of
MAGI-2 and the PDZ binding motif of PTEN.
We performed coimmunoprecipitation experiments of the
endogenous proteins from mouse brain tissue (Fig. 1E). 293T
cells expressing HA-MAGI-2 served to identify the size of
MAGI-2. First, we confirmed that endogenous MAGI-2 protein
was successfully immunoprecipitated by using antisera directed
against the WW domains and immunoblotted with a second
antibody raised against a GST fusion protein spanning the WW
domains and PDZ domains 1 and 2. Endogenous MAGI-2 also
was detected by immunoblotting of whole-cell mouse brain
lysates. If either MAGI-2 antibody was preincubated with the
immunogen before immunoblotting, no signal corresponding to
MAGI-2 was observed (not shown). We observed no MAGI-2
signal when mouse brain lysate was not included in the immu-
noprecipitation, eliminating the possibility that the 180-kDa
band represents Ig. MAGI-2 was detected in immunoprecipi-
tates by using two different antisera directed against PTEN but
not by using antisera against the unrelated protein Akt, indicat-
ing that native MAGI-2yPTEN complexes exist in cells. The
identity of the 100-kDa protein in the MAGI-2 and PTEN
immunoprecipitates is unknown but may represent a MAGI-2
isoform or another MAGUK family member capable of binding
to PTEN.
PTEN and MAGI-2 Are Localized at Tight Junctions. Because PTEN
regulates the PI3-kinaseyAkt pathway through lipid phosphatase
activity, it presumably requires membrane localization to gain
access to its substrates. We addressed this issue in MDCK kidney
epithelial cells because these cells grow as a polarized monolayer
in vitro and form tight junctions, where many MAGUK proteins
are localized. Using confocal microscopy, we observed intense
staining of FLAG-PTEN in discrete membranous regions at the
site of cellular projections (Fig. 2). Diffuse staining also was
observed in the cytoplasm, as previously reported (3, 28).
HA-MAGI-2 was localized primarily at the membrane, but
diffuse nuclear staining also was seen in some cells. Studies using
an antibody against the tight junction protein ZO-1 gave a
membrane staining pattern similar to MAGI-2, supporting the
notion that MAGI-2 is localized to tight junctions, like other
MAGUKs. Dual color staining of transfected 293 cells con-
firmed that PTEN and MAGI-2 colocalize at the membrane (not
shown). The fact that the MAGI-2yPTEN complex is present at
tight junctions is noteworthy in light of evidence that 39 phos-
phoinositides and activated Akt also are localized in this region
of the membrane (32). The significance of the nuclear staining
is unknown but suggests that a fraction of MAGI-2 protein may
shuttle between the membrane and the nucleus. Recent prece-
dent for regulation of MAGUKs in this fashion comes from the
Drosophila discs large protein (DLG) whose membrane local-
ization is regulated by phosphorylation (33).
MAGI-2 Enhances the Efficiency of PTEN in Repression of Akt. The
confocal microscopy studies demonstrate that MAGI-2 and
PTEN both are localized to the plasma membrane at the
appropriate site for access to lipid substrates and regulation of
Akt. If MAGI-2 assembles a signaling complex, we reasoned that
overexpression of MAGI-2 should enhance the efficiency of
PTEN, particularly when present at limiting amounts. We have
observed that PTEN represses Akt activation in 293T cells (16),
and that plasmid doses as low as 100 ng are sufficient to achieve
maximal suppression of the pathway (not shown). We examined
the effect of MAGI-2 in this assay by cotransfection with limiting
doses of PTEN. In the absence of additional MAGI-2, 100 ng of
PTEN plasmid suppressed Akt kinase activity more than 20-fold,
whereas 1 ng had minimal activity, indicating that PTEN was no
longer saturating at this dose. When MAGI-2 plasmid was
added, additional suppression of Akt was observed at the 1-ng
PTEN dose but not at 100 ng (Fig. 3). MAGI-2 had no effect on
Akt activity in the absence of transfected PTEN or when the
PTEN 1–377 mutant, which does not bind MAGI-2, was used.
These data demonstrate that MAGI-2 enhances the activity of
low levels of PTEN. The fact that this effect is not seen at higher
PTEN plasmid doses is most likely because of saturating
amounts of PTEN protein at the membrane when expressed at
supraphysiologic levels.
The PTEN PDZ Binding Motif Is Required for Complete Akt Suppression.
If binding to MAGI-2 plays a role in PTEN function, then
C-terminal PTEN truncation mutants that cannot bind
MAGI-2 should be defective in Akt regulation. We previously
Fig. 2. Subcellular localization of PTEN and MAGI-2. MDCK cells were plated onto fibronectin-treated cover slips, then transfected with FLAG-PTEN or
HA-MAGI-2. After 24 h the cells were washed, fixed in paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked in 3% BSA in PBS containing 1 mM
CaCl2 and 1 mM MgCl2. Cells were incubated in primary antibody in blocking buffer for 1 h at 37°C. Cells were washed in blocking solution plus 0.2% Triton. Cells
were incubated with secondary antibody in blocking buffer for 45 min, washed, and then visualized by using a Zeiss LSM310 laser scanning confocal microscope.











have shown that stable expression of wild-type PTEN blocks
serum-induced Akt activation (16). Consistent with our model,
PTEN 1–377 (Fig. 4A) and PTEN 1–337 (not shown) were
unable to suppress serum-induced Akt activation in this assay.
However, the level of PTEN 1–377 and PTEN 1–337 proteins
was consistently lower than wild-type PTEN in multiple cell
lines and in different cell types. This finding could not be
explained by abnormalities in transcription or translation
because both mutants were expressed at levels comparable to
wild-type PTEN in transient transfection experiments (Fig.
1D). Therefore, we hypothesized that reduced expression was
caused by a change in protein stability. To eliminate any role
of the growth suppressive effect of PTEN (and potential
counterselection against expression), the PTEN 1–377 trun-
cation was engineered into the catalytically inactive C124S
mutant, which is not growth suppressive. In three independent
experiments, the half-life of full-length PTEN C124S protein
was 48–72 h, compared with 12–24 h for PTEN C124S 1–377
(Fig. 4B).
Although the PTEN 1–377 mutant is clearly defective in the
Akt suppression assay, the instability of the protein makes it
difficult to implicate loss of MAGI-2 binding as the mechanism
for loss of function. We noted that PTEN 1–394, which lacks only
the last 9 aa, is expressed at levels comparable to wild-type
PTEN (Fig. 4C). Using the serum-induced Akt activation assay,
we observed that Akt suppression was not as complete in cells
expressing PTEN 1–394 compared with wild-type PTEN at
multiple time points (Fig. 4C). Similar results were obtained in
three independent experiments, and control immunoblots con-
firmed that levels of both Akt and PTEN protein were compa-
rable in all lanes at all time points. These results indicate that
PTEN 1–394 is a partial loss of function mutant and establish a
role for the PDZ-binding motif in maintaining the efficiency of
PTEN-mediated Akt repression.
The PDZ Binding Motif of PTEN Affects Protein Stability. Studies of
the Drosophila scaffold protein InaD indicate that the stability of
its partner proteins are enhanced through PDZ domain-
mediated binding (24). To determine whether the stability of the
PTEN 1–377 mutant is affected by PDZ domain binding, we
added the 7 aa from the C terminus of PTEN (HTQITKV),
which includes the PDZ-binding motif, back to PTEN C124S
1–377 (now called PTEN C124S D377–396). Addition of this
motif restored the PTEN-MAGI-2 interaction in the coimmu-
noprecipitation assay (Fig. 5B). Remarkably, addition of this
motif was sufficient to restore stable, high levels of PTEN C124S
Fig. 3. Effect of MAGI-2 on PTEN activity. (A) 293T cells were transfected with
MAGI-2, HA-Akt, and different concentrations of wild-type or mutant PTEN
plasmid as indicated. The Akt kinase activity was measured by immunopre-
cipitation using an anti-HA antibody, followed by a kinase assay using histone
H2B as substrate. MAGI-2 and HA-Akt expression was verified by immuno-
blotting. (B) Quantitative results from two independent experiments are
shown.
Fig. 4. The PTEN PDZ-binding motif is required for complete Akt suppression. (A) Rat-1 fibroblasts stably expressing wild-type (WT) FLAG-PTEN, FLAG-PTEN
1–377, or Neo control were serum-starved overnight, then challenged with serum for 30 min. Phospho-Akt, total Akt, and PTEN levels were measured by
immunoblot (16). (B) Pulse–chase experiments were performed in 293T cells by transfection with indicated plasmids. PTEN was immunoprecipitated by using
anti-FLAG antibody and visualized by autoradiography. Signals quantitated by a PhosphorImager are shown relative to time 0 of the chase. (C) NIH 3T3 cells stably
expressing indicated PTEN proteins were harvested after serum stimulation at indicated times and processed as described in A, except anti-PTEN antibody (Santa
Cruz Biotechnology) was used to measure PTEN expression.
4236 u www.pnas.org Wu et al.
1–377 protein expression in PTEN-positive and PTEN-negative
cells (Fig. 5C) and to increase the half-life of PTEN C124S 1–377
in pulse–chase experiments (not shown).
Discussion
Our data support a model for regulation of PTEN function
through binding to the MAGUK family protein MAGI-2 (see
Fig. 6, which is published as supplementary material on the
PNAS web site, www.pnas.org). Because MAGI-2 expression
is restricted to certain tissues whereas PTEN is expressed
ubiquitously, there may be other PDZ domain-containing
proteins that bind PTEN (34). This model is conceptually
similar to the regulation of photoreceptor signaling protein
levels in the f ly eye by the multi-PDZ domain scaffold protein
InaD (24). InaD assembles a series of proteins involved in
transmission of photoreceptor signals, each binding a distinct
PDZ domain, into a multisubunit signaling complex. InaD
gene deletion causes a slowed rate of photoreceptor signal
transduction. Flies with InaD alleles containing mutations in
individual PDZ domains express reduced levels of the respec-
tive binding protein, consistent with the notion that binding to
the PDZ domain protects the signaling protein from degra-
dation. Because MAGI-2 contains six potential PDZ domains
and two WW domains, it is likely to bind other proteins in
addition to PTEN. Because WW domains are known to bind
proline-rich motifs as well as phospho-serineythreonine resi-
dues (35, 36), potential MAGI-2-binding proteins are not
restricted to those containing PDZ domain-binding motifs.
Thus, MAGI-2 may function as a scaffold protein that could
assemble a multisubunit signaling complex.
Many mutations in tumors affect the C terminus of PTEN,
including three independent missense mutations that target
the stop codon and result in 8 aa added to the PDZ-binding
motif (37–39). These mutations are predicted to disrupt
binding to PDZ domains. We provide experimental evidence
implicating MAGI-2 in PTEN function by showing that ex-
pression of MAGI-2 enhances the ability of PTEN to suppress
Akt activation. We also demonstrate that PTEN mutants that
fail to bind MAGI-2 are defective in their ability to completely
suppress Akt activation. It is important to note that these
mutants have partial rather than complete loss of function, a
phenotype consistent with the concept that scaffold proteins
optimize activity through a signaling pathway but are not
essential. Studies using C-terminal PTEN truncation mutants
report conf licting results regarding the role of the PDZ-
binding motif (9, 40, 41). However, all of these experiments
rely on overexpression of the mutant PTEN protein, which may
mask any loss of function phenotype that results from failure
to bind a scaffold protein. The most definitive strategy to
address this issue is through targeted mutation in the mouse
germ line. Our data showing partial loss of function would
predict that a PDZ-binding mutant ‘‘knockin’’ may have a less
severe phenotype than the embryonic lethality observed with
complete PTEN knockouts. The recently determined crystal
structure of PTEN shows the presence of a lipid binding C2
domain postulated to play a role in membrane localization
(42). Data presented here are consistent with the hypothesis
that both the C2 domain and the PDZ-binding motif contrib-
ute to the recruitment and maintenance of membrane associ-
ation of PTEN.
Our studies also have uncovered a role for the C terminus
in maintaining protein stability and are in agreement with a
recent report (41). We postulate that these truncations cause
loss of function because of a shortened protein half-life as well
as an inability to dock to a PDZ-domain scaffold protein like
MAGI-2. Studies of PTEN-deficient embryonic stem cells
indicate that a 50% reduction in PTEN protein level may be
sufficient to produce a tumor prone phenotype (18). Our data
with the PTEN 1–394 mutant establish that the PDZ-binding
motif is not required for stability, yet adding the PDZ-binding
motif back to an unstable PTEN truncation mutant is suffi-
cient to restore stability. Alternative considerations include
the potential role of phosphorylation in regulating protein
stability. More work is needed to define the variables that
control PTEN stability.
Inactivation of PTEN through protein destabilization is rem-
iniscent of other tumor suppressors such as p53 and p27Kip1,
which have reduced stability in some cancer cells (43, 44).
Although similar in concept, the PTEN example discussed here
differs in that the genetic abnormality occurs in PTEN itself
rather than in the protein degradation machinery. Certain
human tumors have reduced PTEN protein levels without gene
mutation or loss of mRNA expression (45). Growing evidence
indicates that PTEN inactivation can occur through a range of
mechanisms, including gene deletion or mutation, loss of mRNA
expression, and reduced protein stability.
Fig. 5. The PDZ binding motif of PTEN affects protein stability. (A) Schematic
diagram of PTEN mutants. WT, wild type. (B) Coimmunoprecipitation exper-
iments were performed in 293T cells transfected with the indicated plasmids
as described in Fig. 1. IP, immunoprecipitation. (C) Rat-1 (Upper) and LNCaP
(Lower) cells were infected with retrovirus expressing the indicated PTEN
mutant, then selected in G418. Lysates were analyzed for expression of
FLAG-PTEN at multiple time points. Results from the 25-day time point are
shown.











Loss of function mutations in the Drosophila MAGUK protein
discs large (DLG) cause outgrowths of the imaginal disk, leading
to the concept that DLG functions as a tumor suppressor (46).
Our observation that MAGI-2 enhances PTEN function raises
the possibility that MAGI-2 itself may act as a tumor suppressor.
MAGI-2 has been localized to chromosome 7q21 (26), a region
that is deleted in uterine leiomyomas, prostate cancer, and
glioblastoma (47–50). Definitive tests of this hypothesis will
require analysis of MAGI-2 in clinical material andyor the
creation of MAGI-2 loss-of-function mutations.
Note Added in Proof. The Murine MAGI-2 recently was cloned as
described in ref. 51.
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